BTG (LON:BTG)‘s stock had its “buy” rating reissued by stock analysts at Numis Securities in a research note issued on Thursday. They presently have a GBX 900 ($12.64) price target on the stock. Numis Securities’ price objective would suggest a potential upside of 22.28% from the company’s current price.
Several other brokerages also recently issued reports on BTG. Peel Hunt restated a “hold” rating and issued a GBX 680 ($9.55) target price on shares of BTG in a research report on Tuesday, October 31st. Deutsche Bank restated a “buy” rating and issued a GBX 775 ($10.88) target price on shares of BTG in a research report on Tuesday, November 7th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of BTG in a research report on Wednesday, November 15th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of GBX 774.13 ($10.87).
Shares of BTG (LON BTG) traded down GBX 7.50 ($0.11) during mid-day trading on Thursday, reaching GBX 736 ($10.34). The company’s stock had a trading volume of 178,150 shares, compared to its average volume of 519,802. BTG has a 12 month low of GBX 528.36 ($7.42) and a 12 month high of GBX 784 ($11.01). The firm has a market capitalization of $2,870.00 and a P/E ratio of 3,873.68.
ILLEGAL ACTIVITY WARNING: “Numis Securities Reaffirms “Buy” Rating for BTG (BTG)” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/02/01/numis-securities-reaffirms-buy-rating-for-btg-btg-2.html.
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.